Modulation of ER Stress via cAMP Signaling: Protective Role of Rolipram in Paracetamol-Induced Liver Injury
Abstract
This investigation sought to assess the potential protective function of the phosphodiesterase-4 (PDE) enzyme inhibitor rolipram (ROL) against paracetamol (PARA) induced liver damage, as well as any potential underlying mechanism through modulation of endoplasmic reticulum (ER) stress via cAMP signaling. Fifty-six rats were randomly divided into 7 groups (n = 8). Following 24 h of fasting, animals received three different dosages of ROL (1.25, 2.5, and 5 mg/kg, i.p.) or N-acetylcysteine (140 mg/kg, orally). One hour later, 2 g/kg PARA orally was administered to induce hepatotoxicity. The ELISA method was used to evaluate GSH, PDE4D, and cAMP levels in liver tissue, as well as PDE4D and cAMP levels in serum. In addition, serum levels of liver injury biomarkers, including ALT and AST, were measured. GRP78, IRE1, and CHOP mRNA expressions in tissue samples were assessed using the Real Time PCR technique. The liver tissue's histopathological parameters, including necrosis, bleeding, and mononuclear cell infiltration, were evaluated. The PARA group had higher serum and tissue PDE4 levels, lower cAMP and GSH levels, higher ALT and AST levels, and higher expressions of the ER stress markers GRP78, IRE1, and CHOP mRNA. Histopathological evaluation also revealed severe histopathological damage with PARA toxicity. These changes improved with dose dependent increase of ROL dose. It was evaluated that the protective effect of PDE4 enzyme inhibition on liver injury caused by PARA…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.